r-metHuLeptin
Phase 2Small molecule
r-metHuLeptin is one of 55 small molecule programs targeting Metabolic Syndrome. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Metabolic Syndrome
#DrugCompanyPhaseTrials
1Precose
BayerPhase 3
Zetia
OOrganon and Co
Phase 3
Jardiance
Boehringer IngelheimPhase 3
Glucophage
Boehringer IngelheimPhase 3
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Topamax
WWim Janssens
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
Genotropin
EMD SeronoPhase 3
Rimonabant
SanofiPhase 3
Berberine
XXijing Hospital of Digestive Diseases
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics1 trial
Pharmacokinetics of Leptin Administration During Fasting
Completed·—·Phase 1·NCT00140205·15 enrolled
Immune Response1 trial
Role of Leptin in the Neuroendocrine and Immune Response to Fasting
Completed·—·Phase 1/2·NCT00140231·13 enrolled
Metabolic Syndrome1 trial
Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
Completed·—·Phase 2·NCT00140244·7 enrolled
Amenorrhea1 trial
Study of Leptin for the Treatment of Hypothalamic Amenorrhea
Completed·—·Phase 2·NCT00130117·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for r-metHuLeptin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details